Industry Briefs: Jan. 30, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Jan. 30, 2012
A roundup of other company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Aptar Pharma has opened a new manufacturing site near Mumbai, India. Read More

FDA has approved Pfizer’s Inlyta (axitinib), a kinase inhibitor for treating advanced renal cell carcinoma. Read More

FDA has approved Roche’s Erivedge (vismodegib) capsule for treating advanced basal cell carcinoma. Read More

Lpath has temporarily suspended dosing of iSONEP, for treating age-related macular degeneration, in clinical trials due to cGMP compliance issues at the contract fill–finish source. Read More

Roche has formally issued an offer to acquire all outstanding shares of Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion. Read More

Royal DSM and Indoco Remedies have formed a commercialization agreement for eight APIs. Read More

Valeant Pharmaceuticals has withdrawn its offer to acquire ISTA Pharmaceuticals for $7.50 per share in cash. Read More

Watson Pharmaceuticals announced plans to establish a New Jersey-based R&D technology center to support generic-drug pharmaceutical product development. Read More

People News

GlaxoSmithKline has announced changes to its board of directors. Read More

Octagon Research Solutions has appointed Gina L. Schmidt to manage the company’s global regulatory services division. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here